The safety of semaglutide in patients with depression and obesity

赛马鲁肽 肥胖 医学 萧条(经济学) 内科学 糖尿病 内分泌学 2型糖尿病 利拉鲁肽 经济 宏观经济学
作者
Ziyi Yang,Yimin Yan
出处
期刊:Obesity [Wiley]
卷期号:32 (12): 2217-2217
标识
DOI:10.1002/oby.24142
摘要

TO THE EDITOR: The bidirectional relationship between obesity and depression is complex, with each condition potentially exacerbating the other and increasing their respective pathogenic risks [(1)]. The treatment of patients with obesity and depression is particularly challenging due to the unique characteristics of this patient population. Semaglutide, an emerging treatment option, has shown significant potential in weight management and blood glucose control [(2)]. Therefore, evaluating its safety in patients with depression is crucial. The safety of semaglutide has been a topic of significant debate in recent literature for patients with both depression and obesity. The case study by Li et al. reported depressive symptoms following the use of semaglutide in patients without a history of depression, suggesting that the drug may trigger depressive episodes in susceptible individuals [(3)]. This finding has raised concerns regarding its clinical use. However, based on my clinical experience and a comprehensive review of existing literature, I remain confident in the safe use of semaglutide in patients with comorbid depression and obesity. The study by Kushner et al. confirmed the weight loss effects of semaglutide in adults with overweight and obesity, noting that its adverse event profile remained consistent regardless of antidepressant use [(1)]. Additionally, Furlan et al. supported the potential of glucagon-like peptide-1 (GLP-1) therapy in weight management for psychiatric patients. Notably, GLP-1 is not metabolized through cytochrome P450 in the liver, thereby reducing the risk of drug interactions [(4)]. The study by Chen et al. suggested potential antidepressant effects of GLP-1 receptor agonists, although the exact mechanism remains unclear [(5)]. Other reports have also reached similar conclusions, with some speculating that GLP-1 receptor agonists may help alleviate depressive symptoms. By reducing weight and improving metabolic parameters, semaglutide can enhance the quality of life for patients and mitigate the weight gain associated with psychotropic drugs. Existing evidence suggests that semaglutide is safe and effective for patients with obesity, including those who are on antidepressants [(1)]. However, clinicians should remain vigilant and monitor for potential psychological side effects, especially in patients with a history of depression or new psychiatric symptoms. Given the efficacy of semaglutide in correcting metabolic disorders and promoting weight loss, continued research is essential, particularly focusing on its long-term safety and efficacy. The authors declared no conflict of interest.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
WTX发布了新的文献求助10
刚刚
打打应助zhaoyali采纳,获得10
刚刚
wumengxin完成签到 ,获得积分10
刚刚
1秒前
lagom发布了新的文献求助10
1秒前
liuminyi发布了新的文献求助10
2秒前
Owen应助视野胤采纳,获得10
2秒前
2秒前
刘澳发布了新的文献求助10
2秒前
Zww完成签到,获得积分20
3秒前
俞若枫完成签到,获得积分0
4秒前
Akim应助小奶采纳,获得10
4秒前
情怀应助吧噗采纳,获得10
4秒前
遐蝶发布了新的文献求助10
4秒前
4秒前
tgd完成签到,获得积分10
5秒前
奔波儿灞完成签到,获得积分20
5秒前
深情安青应助凯文采纳,获得10
6秒前
6秒前
二三事完成签到,获得积分10
6秒前
6秒前
6秒前
6秒前
7秒前
华仔应助axn采纳,获得10
7秒前
852应助wj采纳,获得10
7秒前
gmaster完成签到,获得积分10
7秒前
7秒前
不眠的人完成签到,获得积分10
8秒前
奔波儿灞发布了新的文献求助10
8秒前
orixero应助Han采纳,获得10
8秒前
mio关注了科研通微信公众号
9秒前
能量球发布了新的文献求助10
9秒前
孙夕然发布了新的文献求助10
10秒前
liuminyi完成签到,获得积分10
10秒前
888886kn发布了新的文献求助10
11秒前
子非鱼发布了新的文献求助10
11秒前
疾风发布了新的文献求助10
11秒前
11秒前
12秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974856
求助须知:如何正确求助?哪些是违规求助? 3519400
关于积分的说明 11198085
捐赠科研通 3255563
什么是DOI,文献DOI怎么找? 1797860
邀请新用户注册赠送积分活动 877208
科研通“疑难数据库(出版商)”最低求助积分说明 806219